What Has Been The Historical And Current Growth Of The Viral And Non-Viral Vector Manufacturing Market?
The viral and non-viral vector manufacturing market has seen considerable growth due to a variety of factors.
•The market size for viral and non-viral vector manufacturing has expanded drastically in the past couple of years. It is projected to increase from $8.67 billion in 2024 to $10.3 billion in 2025, indicating a compound annual growth rate (CAGR) of 18.8%.
The considerable growth observed in the historical period can be related to the escalating occurrence of genetic diseases, advancements in the field of biotechnology, a surge in gene therapy research investments, a wider recognition of personalized medicine, and the regulatory bodies' aid for the development of gene therapy.
What Is The Forecast For The Viral And Non-Viral Vector Manufacturing Market By 2029?
The viral and non-viral vector manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for manufacturing of viral and non-viral vectors is poised to witness a massive surge over the coming years, expanding to a value of $22.06 billion in 2029 at a compound annual growth rate of 21.0%.
This predicted growth can be accredited to several factors, which includes the escalating demand for gene therapies, the widening application in the treatment of rare diseases, a surge in investments in biomanufacturing infrastructure, and the increasing embrace of precision medicine. Significant trends forecasted during this period involve the innovation of next-generation viral vectors, the escalating utilization of CRISPR or cas9 technology in vector manufacturing, emphasis on scalability and economical manufacturing procedures, growing use of non-viral vectors, and progress in cell and gene therapy manufacturing technologies.
Which Drivers Are Accelerating Growth In The Viral And Non-Viral Vector Manufacturing Market?
The rising occurrence of genetic anomalies is projected to fuel the expansion of the viral and non-viral vector manufacturing markets. Genetic anomalies represent conditions that are wholly or partly induced by variations from the standard DNA sequence. Viral vectors administer remedial genes to specific cells, superseding or amplifying faulty genes responsible for genetic diseases. Typically, non-viral vectors are deployed in ex vivo gene therapy procedures where cells are genetically altered outside the body prior to reinfusion into a patient. To illustrate, as per records by the International Diabetes Federation, a Belgium-based diabetes federation in June 2022, the global occurrence of diabetes had climbed to 10.5%, with more than half (44.7%) remaining undiagnosed and nearly 783 million adults, or one-eighth of the population, anticipated to be afflicted by 2045. Consequently, the escalating prevalence of genetic disorders stimulates the progression of the viral and non-viral vector production market.
What Are The Core Segments Of The Global Viral And Non-Viral Vector Manufacturing Market?
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors
Pre-Book The Viral And Non-Viral Vector Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Viral And Non-Viral Vector Manufacturing Market Size?
The emergence of technological innovations is a predominant trend observed in the viral and non-viral vector manufacture industries. Leading corporations in these markets are striving for technological breakthroughs in order to maintain their market standing. For example, in August 2022, Merck KGaA, a scientific and technological corporation based in Germany, introduced their VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This company is among the first Contract Development and Manufacturing Organisations and technology pioneers to deliver a comprehensive package for viral vector production, covering elements like AAV, Lentiviral, CDMO, CTO, and process development. This advanced platform allows biopharmaceutical firms to reduce process development costs and time, thereby expediting their journey to clinical manufacture.
Who Are the Key Players in the Viral And Non-Viral Vector Manufacturing Market?
Major companies operating in the viral and non-viral vector manufacturing market include:
• Novartis AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• FUJIFILM Holdings Corporation
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Lonza Group AG
• WuXi AppTec Co Ltd.
• Catalent Inc.
• Sartorius AG
• Charles River Laboratories Inc.
• Sarepta Therapeutics Inc.
• GenScript ProBio Co. Ltd.
• TAKARA BIO Inc.
• Oxford BioMedica plc
• Beam Therapeutics Inc.
• Intellia Therapeutics Inc.
• MaxCyte Inc.
• Voyager Therapeutics Inc.
• Genethon
• MeiraGTx Holdings plc
• Evox Therapeutics Ltd.
• Entos Pharmaceuticals Inc.
• LogicBio Therapeutics Inc.
• bluebird bio Inc.
• 4D Molecular Therapeutics Inc.
• Precision NanoSystems Inc.
• GenSight Biologics S.A.
• Abeona Therapeutics Inc.
• Generation Bio Co.
What are the Regional Insights into the Viral And Non-Viral Vector Manufacturing Market?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
